Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: A report from the children's oncology group

Pediatric Blood and Cancer

Volumn 55, Issue 6, 2010, Pages 1066-1071

  Pollack, Ian F ^a   Hamilton, Ronald L ^a   Sobol, Robert W ^a   Nikiforova, Marina N ^a   Nikiforov, Yuri E ^a   Lyons Weiler, Maureen A ^b   LaFramboise, William A ^a,b   Burger, Peter C ^c   Brat, Daniel J ^d   Rosenblum, Marc K ^e   Gilles, Floyd H ^f   Yates, Allan J ^g   Zhou, Tianni ^h   Cohen, Kenneth J ⁱ   Finlay, Jonathan L ^f   Jakacki, Regina I ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f CHILDREN S HOSPITAL LOS ANGELES   (United States)

^g OHIO STATE UNIVERSITY   (United States)

^h CHILDREN S ONCOLOGY GROUP   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Anaplastic glioma; Childhood; Glioblastoma; MGMT; Microsatellite instability; Mismatch repair; Treatment resistance

Indexed keywords

LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PREDNISONE; TEMOZOLOMIDE; VINCRISTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CHILD; CLINICAL ASSESSMENT; GENE LOCUS; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INCIDENCE; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; MICROSATELLITE MARKER; MISMATCH REPAIR; OUTCOME ASSESSMENT; PEDIATRICS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS, ALKYLATING; CHILD; DACARBAZINE; DNA MISMATCH REPAIR; DRUG RESISTANCE, NEOPLASM; GLIOMA; HUMANS; MICROSATELLITE INSTABILITY; MICROSATELLITE REPEATS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PROGNOSIS;

EID: 77958579289     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22634     Document Type: Article

References (58)

1. Pollack IF. Current concepts: Brain tumors in children. N Engl J Med 1994; 331: 1500-1507.
2. Pollack IF, Hamilton RL, James CD, et al. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: Results from the Children's Cancer Group 945 cohort. J Neurosurg Pediatr 2006; 105: 3431-3437.
3. Sung T, Miller DC, Hayes RL, et al. Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas. Brain Pathol 2000; 10: 249-259.
4. Bredel M, Pollack IF, Hamilton RL, et al. Epidermal growth factor receptor (EGFR) expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin Cancer Res 1999; 5: 1786-1792.
5. Cheng Y, Ng H-K, Zhang S-F, et al. Genetic alterations in pediatric high-grade astrocytomas. Hum Pathol 1999; 30: 1284-1290.
6. Raffel C, Frederick L, O'Fallon JR, et al. Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. Clin Cancer Res 1999; 5: 4085-4090.
7. Sure U, Ruedi D, Tachibana O, et al. Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas. J Neuropathol Exp Neurol 1997; 56: 782-789.
8. Pollack IF, Finkelstein SD, Woods J, et al. Expression of p53 and prognosis in malignant gliomas in children. N Engl J Med 2002; 346: 420-427.
9. Pollack IF, Finkelstein SD, Burnham J, et al. The association between chromosome 1p loss and outcome in pediatric malignant gliomas: Results from the CCG-945 cohort. Pediatr Neurosurg 2003; 39: 114-121.
10. Collins VP. Progression as exemplified by human astrocytic tumors. Semin Cancer Biol 1999; 9: 267-276.
11. 1-S transition control gene abnormalities. Cancer Res 2000; 60: 417-424.
12. von Deimling A, von Ammon K, Schoenfeld D, et al. Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 1993; 3: 19-26.
13. Watanabe K, Tachibana O, Sato K, et al. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996; 6: 217-224.
14. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-1812.
15. Sposto R, Ertel IJ, Jenkin RDT, et al. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: Results of a randomized trial. A report from the Children's Cancer Study Group. J Neuro-Oncol 1989; 7: 165-177.
16. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
17. Cohen KJ, Heideman R, Zhou T, et al. Should temozolomide be the standard of care for children with newly diagnosed high-grade gliomas? Results of the Children's Oncology Group ACNS0126 study. Neuro-Oncology 2007; 9: 188 (abstract).
18. Wedge SR, Porteus JK, May BL, et al. Potentiation of temozolomide and BCNU toxicity by O(6)-benzyl-guanine: A comparative study in vitro. Br J Cancer 1996; 73: 482-490.
19. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343: 1350-1354.
20. Hegi ME, Diserens A-C, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004; 10: 1871-1874.
21. Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
22. Belanich M, Pastor M, Randall T, et al. Retrospective study of the correlation between DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 1996; 56: 783-788.
23. Jaeckle KA, Eyre HJ, Townsend JJ, et al. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: A Southwest Oncology Group study. J Clin Oncol 1998; 16: 3310-3315.
24. 6-Methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1, 3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin Cancer Res 2003; 9: 1461-1468.
25. Hotta T, Saito Y, Fujita H, et al. O6-Alkylguanine-DNA alkyltransferase activity of human malignant glioma and its clinical implications. J Neuro-Oncol 1994; 21: 135-140.
26. 6-Methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: Results from the CCG-945 cohort. J Clin Oncol 2006; 24: 3431-3437.
27. Alonso M, Hamelin R, Kim M, et al. Microsatellite instability occurs in distinct subtypes of pediatric but not adult central nervous system tumors. Cancer Res 2001; 61: 2124-2128.
28. Eckert A, Kloor M, Giersch A, et al. Microsatellite instability in pediatric and adult high-grade gliomas. Brain Pathol 2007; 17: 146-150.
29. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96: 261-268.
30. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: Development of international criteria for determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248-5257.
31. Zhang J, Lindroos A, Ollila S, et al. Gene conversion is a frequent mechanism of inactivation of the wild-type allele in cancers from MLH1/MSH2 deletion carriers. Cancer Res 2006; 66: 659-664.
32. Hamilton SR, Liu B, Parsons RE, et al. The molecular basis of Turcot's syndrome. N Engl J Med 1995; 332: 839-847.
33. Gomori E, Fulop Z, Meszaros I, et al. Microsatellite analysis of primary and recurrent glial tumors suggests different modalities of clonal evolution of glioma cells. J Neuropath Exp Neurol 2002; 61: 396-402.
34. Dams E, Van de Kelft EJZ, Martin JJ, et al. Instability of microsatellites in human gliomas. Cancer Res 1995; 55: 1547-1549.
35. Martinez R, Schackert HK, Plaschke J, et al. Molecular mechanisms associated with chromosomal microsatellite instability in sporadic glioblastoma multiforme. Oncology 2004; 66: 395-403.
36. Mizoguchi M, Inamura T, Ikezaki K, et al. Patient survival and microsatellite instability in gliomas by high-resolution fluorescent analysis. Oncol Rep 1999; 6: 791-795.
37. Lunden DA, Blank A, Berger MS, et al. Microsatellite instability is infrequent in sporadic adult gliomas. Oncol Res 1998; 10: 421-428.
38. Maxwell JA, Johnson SP, McLendon RE, et al. Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. Clin Cancer Res 2008; 14: 4859-4868.
39. Leung SY, Chan TL, Chung LP, et al. Microsatellite instability and mutation of DNA mismatch repair genes in gliomas. Am J Pathol 1998; 153: 1181-1188.
40. Kanamori M, Kon H, Nobukuni T, et al. Microsatellite instability and the PTEN1 gene mutation in a subset of early onset gliomas carrying germline mutation or promoter methylation of the hMLH1 gene. Oncogene 2000; 19: 1564-1571.
41. Blaeker H, Rasheed BKA, McLendon RE, et al. Microsatellite analysis in childhood brain tumors. Genes Chromosomes Cancer 1996; 15: 54-63.
42. Amariglio N, Friedman E, Mor O, et al. Analysis of microsatellite repeats in pediatric brain tumors. Cancer Genet Cytogenet 1995; 84: 56-59.
43. Finlay JL, Boyett JM, Yates AJ, et al. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. J Clin Oncol 1995; 13: 112-123.
44. Bianchi F, Galizia E, Catalani R, et al. CAT25 is a mononucleotide marker to identify HNPCC patients. J Mol Diagn 2009; 11: 248-252.
45. Thorland EC, Thibodeau SN. Hereditary nonpolyposis colorectal cancer. In: Molecular pathology for clinical practice. Leonard DGB (ed): Springer; 2007. pp. 223-232.
46. Pollack IF, Hamilton RL, Burnham J, et al. Molecular predictors of outcome in childhood malignant gliomas: The Children's Oncology Group experience. Neuro-Oncology 2007; 9: 188.
47. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin embedded tissues: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991; 39: 741-748.
48. 6-alkylguanine-DNA alkyltransferase using newly developed monoclonal antibodies. Cancer Res 1990; 50: 58-61.
49. 6-methylguanine-DNA methyltransferase in formalin-fixed, paraffin-embedded astrocytomas. Lab Invest 1998; 78: 643-644.
50. Hsu S, Raine L, Fanger H, et al. Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase techniques. J Histochem Cytochem 1981; 29: 577-580.
51. Pollack IF, Boyett JM, Yates AJ, et al. The influence of central review on outcome associations in childhood malignant gliomas: Results from the CCG-945 experience. Neuro-Oncology 2003; 5: 197-207.
52. Middlemas DS, Stewart CF, Kirstein MN, et al. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin Cancer Res 2000; 6: 998-1007.
53. Wedge SR, Porteous JK, Newlands ES. 3-Amino-benzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair deficiency and O6-alkylguanine-DNA alkyltransferase activity. Br J Cancer 1997; 57: 2933-2936.
54. Friedman HS, McLendon RE, Kerby T, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodol in newly diagnosed malignant glioma. J Clin Oncol 1998; 16: 3851-3857.
55. Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res 2009; 15: 4622-4629.
56. Hunter C, Smith R, Cahill DP, et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 2006; 66: 3987-3991.
57. Bobola MS, Emond MJ, Blank A, et al. Apurinic endonuclease activity in adult gliomas and time to tumor progression after alkylating agent-based chemotherapy and after radiotherapy. Clin Cancer Res 2004; 10: 7875-7883.
58. Batista LFZ, Roos WP, Christmann M, et al. Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks. Cancer Res 2007; 67: 11886-11895.